For the quarter ending 2025-09-30, TMCI made $50,214K in revenue. -$16,255K in net income. Net profit margin of -32.37%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 50,214 | 47,387 | 52,570 | 54,757 |
| Cost of goods sold | 10,508 | 9,635 | 10,677 | 10,713 |
| Gross profit | 39,706 | 37,752 | 41,893 | 44,044 |
| Sales and marketing | 34,421 | 33,084 | 36,122 | 38,289 |
| Research and development | 4,680 | 5,498 | 5,562 | 5,209 |
| General and administrative | 16,281 | 16,144 | 15,791 | 14,064 |
| Total operating expenses | 55,382 | 54,726 | 57,475 | 57,562 |
| Loss from operations | -15,676 | -16,974 | -15,582 | -13,518 |
| Interest income | 634 | 775 | 841 | 1,270 |
| Interest expense | 1,338 | 1,321 | 1,311 | 1,314 |
| Other income, net | 92 | 122 | 130 | 101 |
| Other non-operating income (expense), net | -612 | -424 | -340 | 57 |
| Net loss | -16,288 | -17,398 | -15,922 | -13,461 |
| Unrealized gain (loss) on marketable securities | 33 | -7 | -40 | -94 |
| Comprehensive loss | -16,255 | -17,405 | -15,962 | -13,555 |
| Net loss per share attributable to common stockholders, basic | -0.26 | -0.28 | -0.25 | -0.217 |
| Net loss per share attributable to common stockholders, diluted | -0.26 | -0.28 | -0.25 | -0.217 |
| Weighted-average common stock outstanding, basic | 63,515,372 | 63,006,891 | 62,661,447 | -39,142 |
| Weighted-average common stock outstanding, diluted | 63,515,372 | 63,006,891 | 62,661,447 | -39,142 |
TREACE MEDICAL CONCEPTS, INC. (TMCI)
TREACE MEDICAL CONCEPTS, INC. (TMCI)